May. 10 at 7:56 PM
$IFRX Guggenheim comments Friday afternoon….
“…further substantiates Izicopan as a safer alternative, with likely minimal hepatotoxicity profile.
Given the well-manifested pathophysiology of C5a/C5aR driving the inflammatory
circuit of AAV, coupled with Izicopan's competitive drug profile,
we believe Izicopan
has the potential to improve upon
$AMGN TAVENOS
$1.3B global peak sale estimate. IFRX
is beginning to plan for a Phase IIb development in AAV along
with open-labeled studies across broader complement-mediated renal diseases (clinical data expected starting 2027 for certain indications). Furthermore,
$IFRX
discussed an optionality for expedited clinical & regulatory path that could include a
seamless trial for a "one-shot" Phase II/III registrational approach, which could
potentially reduce time to commercialization by 6-12 months”
My 2 cents:
Cld Amgen be a buyers to replace avacopan ?
Does the company now get properly valued?
Guggenheim price target now
$14 even w OS
